• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Nephrology

The ZEUS study: everolimus maintains durable renal transplant function

bySayed ImtiazandChaz Carrier
December 25, 2014
in Nephrology, Surgery
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Conversion at 4.5 months following kidney transplant from cyclosporine (a calcineurin inhibitor) to everolimus (a mTOR pathway inhibitor) maintains improved renal function at 5-year follow-up

2. Although post-conversion everolimus therapy was associated with an increased the rate of acute rejection, it was reversible and did not affect long term outcomes

Evidence Rating Level: 1 (Excellent)

Study Rundown: Due to the significant nephrotoxic effects of Cyclosporine (CsA), a calcineurin inhibitor (CNI), the benefits of post-transplant immunosuppression on graft survival must be weighed against the risk of decreased graft function. Everolimus (an mTOR inhibitor) is less nephrotoxic and early conversion within the first 6 months post-transplant is linked to improved estimated glomerular filtration rate (eGFR) compared to CsA. Previous studies only showed short term 1-year follow-up of CNI sparing therapy while in the ZEUS study patients were followed for 5 years.

Strengths of the study included randomization to either CsA or everolimus, long term follow-up and post-hoc analysis of patients that remained in their study arm of immunosuppression during the study period. Limitations included the effects of acute rejection and adverse effects on graft survival when patients switched immunosuppressive regimen. Additional limitations included the low rate of monitoring for drug specific antibodies so the rate of chronic rejection could not be monitored.

Click to read the study in The American Journal of Transplantation

Relevant Reading: A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients.

RELATED REPORTS

No observed benefit of adjuvant everolimus combined with endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer

#VisualAbstract: Addition of everolimus to letrozole improves survival in patients with HR⁺ breast cancer and disease progression on tamoxifen

#VisualAbstract: Everolimus plus leuprorelin and letrozole improves progression-free survival in HR⁺, HER2⁻ metastatic breast cancer patients with visceral metastases

In-Depth [randomized controlled trial]: This study randomized 300 allograft kidney transplant recipients, 18-65 years of age, to either continue CsA or switch to everolimus at 4.5 months post-transplant. Estimated GFR was measured at baseline and at various time points for 5 years. Overall 5-year follow-up eGFR of everolimus was 5.3mL/min/1.73m^2 higher (95%CI 2.4, 8.3; p<0.001) than that of CsA. However, a number of patients switched immunosuppression due to acute rejection or adverse events. Therefore, in post-hoc analysis patients who remained in their study arm included 77/123 (62.6%) of everolimus and 84/109 (77.1%) of CsA patients. With adjustment for compliance, eGFR was higher for everolimus at 8.2mL/min/1.73m^2 (95% CI 4.3, 12.1; p<0.001). There was 21% loss to follow-up in the everolimus group and 25% loss to follow-up in the CsA group at the 5-year visit (reasons included withdrawing consent and death). Serious adverse events (pneumonia, UTI, nasopharyngitis and gastroenteritis) occurred in 17.4% vs. 11.7% of patients in the everolimus and CsA group respectively. Overall mortality of patients was low in both arms (<3%). Notably, the rate of acute rejection was far higher for everolimus (15.6%- majority Banff grade I) vs. CsA (7.5% p=0.032)

More from this author:  Thromboelastography velocity better for predicting hyperfibrinolysis in trauma; Previous stroke may increase risk of complications after major surgery

Image: PD

©2014 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: Cyclosporineeverolimustransplant surgery
Previous Post

Radiologist recommendations often yield significant findings

Next Post

Childhood adversity linked with increased adult psychiatric medication use

RelatedReports

Adjunctive TMP-SMX (Bactrim) associated with higher clinical cure rates for cutaneous abscesses
Oncology

No observed benefit of adjuvant everolimus combined with endocrine therapy for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer

May 30, 2022
#VisualAbstract: Addition of everolimus to letrozole improves survival in patients with HR⁺ breast cancer and disease progression on tamoxifen
StudyGraphics

#VisualAbstract: Addition of everolimus to letrozole improves survival in patients with HR⁺ breast cancer and disease progression on tamoxifen

October 13, 2021
#VisualAbstract: Everolimus plus leuprorelin and letrozole improves  progression-free survival in HR⁺, HER2⁻ metastatic breast cancer patients with visceral metastases
StudyGraphics

#VisualAbstract: Everolimus plus leuprorelin and letrozole improves progression-free survival in HR⁺, HER2⁻ metastatic breast cancer patients with visceral metastases

January 13, 2021
Novel biodegradable sirolimus-eluting stents non-inferior to durable everolimus-eluting stents [BIOSCIENCE trial]
Weekly Rewinds

2 Minute Medicine Rewind December 12, 2016

December 15, 2016
Next Post
Social integration may reduce suicide risk in male health professionals

Childhood adversity linked with increased adult psychiatric medication use

Pediatric reptile-associated salmonellosis a substantial burden

Pediatric reptile-associated salmonellosis a substantial burden

Pediatric cardiac surgery occurring at earlier age, with better outcomes over 50+ year review

Pediatric cardiac surgery occurring at earlier age, with better outcomes over 50+ year review

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
  • Sodium-glucose cotransporter 2 inhibitors may reduce incidence of obstructive airway disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options